Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,209.92 +37.77 (+0.46%) Bitcoin USD
59,130.28 +843.05 (+1.45%) CMC Crypto 200
1,276.84 -0.14 (-0.01%)
Ocugen, Inc. (OCGN)
Pre-market:
| Previous close | 1.3900 |
| Open | 1.4057 |
| Bid | 1.3200 x 3400 |
| Ask | 1.3500 x 4900 |
| Day's range | 1.3200 - 1.4100 |
| 52-week range | 0.3450 - 2.1050 |
| Volume | |
| Avg. volume | 9,819,339 |
| Market cap | 339.673M |
| Beta (5Y monthly) | 3.74 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2600 |
| Earnings date | 03 May 2024 - 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.67 |
GlobeNewswireOcugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
MALVERN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen will speak at the Retina World Congress (RWC) being held May 9-12, 2024 in Ft. Lauderdale, FL. “This is a terrific opportunity to share the most recent developments in mo
- GlobeNewswire
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Benjamin Bakall, MD, PhD, Director of Clinical Research at Associated Retina Consultants and Clinical Assistant Professor at the University of Arizona, College of Medicine—Phoenix will present data from the OCU400 Phase 1/2 clinical trial at the Retinal
ZacksOcugen (OCGN) to Report Q1 Earnings: What's in the Cards?
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.
